Market Price

36.58 

-1.13 -3.0%

as of Sep 17 '19

52 Week Range:

33.17 79.17


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 4.57
5.60
9.97
9.51
9.21
13.06
growth rate 22.5% 78.0% -4.6% -3.2% 41.8%
Earnings BIT -16.50
-22.93
-38.83
-54.13
-118.70
-200.99
-320.79
-362.48
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -8.60
-8.60
-8.60
-8.60
-10.18
-10.18
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -13.78
-16.47
-25.76
-15.44
-25.82
-38.20
-51.02
-46.99
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -146.55
-19.25
-30.60
-56.41
-85.73
-65.10
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -146.74
-19.32
-30.85
-57.12
-87.40
-68.20
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 3.96
3.71
4.60
5.89
6.38
6.33
4.69
6.56
growth rate -6.3% 24.0% 28.0% 8.3% -0.8% -25.9% 39.9%
Quick Ratio 3.72
3.64
4.53
5.81
6.21
6.22
4.51
6.37
growth rate -2.2% 24.5% 28.3% 6.9% 0.2% -27.5% 41.2%
Leverage 1.53
1.16
1.22
1.73
1.64
1.25
growth rate -24.2% 5.2% 41.8% -5.2% -23.8%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 10.62
1.25
0.48
10.33
8.23
4.89
3.67
10.44
growth rate -88.3% -61.8% 2,070.8% -20.4% -40.6% -24.9% 184.5%
Acct.Payable 22.99
9.89
11.73
11.07
14.75
17.11
22.77
17.88
growth rate -57.0% 18.6% -5.6% 33.3% 16.0% 33.1% -21.5%
Cur.Assets 190.59
130.14
169.75
359.55
337.33
559.89
445.26
613.78
growth rate -31.7% 30.4% 111.8% -6.2% 66.0% -20.5% 37.9%
Total Assets 194.47
137.01
201.21
491.90
420.07
619.09
614.40
858.46
growth rate -29.6% 46.9% 144.5% -14.6% 47.4% -0.8% 39.7%
Cash 117.66
91.30
71.56
14.03
71.76
160.75
102.72
70.50
growth rate -22.4% -21.6% -80.4% 411.5% 124.0% -36.1% -31.4%
Inventory 0.87
growth rate
Cur.Liabilities 48.16
35.11
36.93
61.09
52.89
88.43
94.94
93.50
growth rate -27.1% 5.2% 65.4% -13.4% 67.2% 7.4% -1.5%
Liabilities 131.33
93.11
69.72
67.54
74.95
260.50
238.89
170.92
growth rate -29.1% -25.1% -3.1% 11.0% 247.6% -8.3% -28.5%
Equity 131.48
424.37
345.12
358.59
375.50
687.54
growth rate 222.8% -18.7% 3.9% 4.7% 83.1%
Common Shares 23.00
23.00
15.00
34.00
37.00
39.00
47.00
57.00
growth rate 0.0% -34.8% 126.7% 8.8% 5.4% 20.5% 21.3%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 1.91
1.48
1.29
2.22
20.16
9.92
4.63
6.99
growth rate -22.6% -12.3% 71.3% 809.9% -50.8% -53.3% 51.0%
Cash From OA -59.35
-76.95
38.56
-285.23
-304.42
growth rate 0.0% 100.0% -100.0% 0.0%
FCF per Share -1.79
-2.02
-2.00
1.27
-5.93
-5.66
growth rate 0.0% 0.0% 100.0% -100.0% 0.0%
Sale Purchase of Stock 77.36
0.14
123.88
335.88
6.58
170.01
284.47
growth rate -99.8% 87,139.4% 171.1% -98.0% 2,483.7% 67.3%
FCF -17.00
-51.00
-58.00
-62.00
-97.00
29.00
-290.00
-311.00
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 21.84
25.11
25.55
65.36
59.12
69.89
43.01
94.39
growth rate 15.0% 1.8% 155.8% -9.6% 18.2% -38.5% 119.5%
Op.Income -23.71
-20.10
-39.41
-54.13
-118.70
-200.99
-320.79
-362.48
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -16.50
-22.93
-38.83
-53.93
-117.73
-198.47
-314.67
-346.03
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -23.71
-20.10
-39.41
-53.50
-117.73
-198.47
-314.67
-346.03
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -1.15
-1.17
-2.83
-1.59
-3.15
-5.07
-6.75
-6.03
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 21.84
25.11
25.55
-35.01
-82.71
-150.27
-249.67
-248.33
growth rate 15.0% 1.8% -100.0% 0.0% 0.0% 0.0% 0.0%
R&D 31.25
41.04
54.50
100.37
341.32
341.32
341.32
341.32
growth rate 31.3% 32.8% 84.2% 240.1% 0.0% 0.0% 0.0%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT -72.95
-99.16
-96.36
-97.48
-113.86
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 21.34
8.33
10.44
11.66
14.71
growth rate -61.0% 25.4% 11.7% 26.1%
Acct.Payable 17.32
16.62
17.88
12.41
15.44
growth rate -4.1% 7.6% -30.6% 24.4%
Cur.Assets 753.78
695.54
613.78
557.10
533.71
growth rate -7.7% -11.8% -9.2% -4.2%
Total Assets 998.24
929.08
858.46
822.13
783.87
growth rate -6.9% -7.6% -4.2% -4.7%
Cash 210.32
156.48
70.50
103.44
83.58
growth rate -25.6% -54.9% 46.7% -19.2%
Inventory 0.86
0.87
2.33
4.66
growth rate 0.7% 167.9% 100.1%
Cur.Liabilities 84.87
84.75
93.50
80.91
89.50
growth rate -0.2% 10.3% -13.5% 10.6%
Liabilities 175.09
168.87
170.92
201.87
251.19
growth rate -3.6% 1.2% 18.1% 24.4%
LT Debt 66.01
growth rate
Equity 823.14
760.21
687.54
620.26
532.68
growth rate -7.6% -9.6% -9.8% -14.1%
Common Shares 0.06
0.06
0.06
0.06
0.06
growth rate 0.0% 0.0% 1.7% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 1.36
3.14
1.05
2.04
1.27
growth rate 130.7% -66.5% 93.5% -37.6%
Cash From OA -67.40
-63.84
-74.19
-103.27
-88.15
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 9.71
growth rate
FCF -68.76
-66.98
-75.24
-105.31
-89.42
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 40.41
15.20
30.01
30.23
26.22
growth rate -62.4% 97.5% 0.7% -13.3%
Op.Income -72.95
-99.16
-96.36
-97.48
-113.86
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -68.75
-94.66
-91.79
-93.08
-109.87
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -68.75
-94.66
-91.79
-93.08
-109.87
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit -46.32
-68.06
-64.50
-65.69
-81.47
growth rate 0.0% 0.0% 0.0% 0.0%
R&D 93.81
93.81
93.81
growth rate 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (17.27)

YOY Growth Grade:

F (1.06)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -10.18 -5.48 -5.53
EPS / Growth 0.0% -6.67

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 39.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 19.9% 19.9%
Future PE 0.00 0.01 13.30
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.